Abbreviations used: AlC, Akaike information criterion; BV, blood volume; [ " ClMeNTI, NI'-(e IC]methyl) naltrindole; %COV, percent coefficient of variation; PET, positron emission tomography.
Summary: The regional binding of NI' -(["C]methyl)naltrin dole (MeNTI), a selective o-opioid antagonist, was studied in healthy human subjects with positron emission tomography (PET). After the bolus intravenous administration of high specific activity e I ClMeNTI, PET was performed over 90 minutes. Arterial plasma samples were obtained during the scanning period and assayed for the presence of radiolabeled metabolites. The data were analyzed with various kinetic (two and three-corr'ipartment models, Patlak graphical analysis) and nonkinetic (apparent volume of distribution and activity at a late scanning time) approaches. This tracer showed irreversible binding characteristics during the scanning period used. The results of the analyses also were compared with the density and Changes in the function or number of opioid receptors have been proposed in several neuropsychiatric and neu rode generative conditions, including Parkinson's, Hun tington's, and Alzheimer's diseases (Gulya, 1990) ; sub stance abuse (Kosten, 1990) ; and seizure disorders (May berg et aI., 1991) . Three primary opioid receptor sUbtypes have been described pharmacologically and subsequently cloned: mu (fL), delta (8), and kappa (K) (Rei sine and Bell, 1993) .
Considerable advances have been made in the devel opment of radiotracers for the measurement of central opioid receptor densities in living human subjects using positron emission tomography (PET) (Mayberg and Frost, 1990) . [llC] Carfentanil, a selective fL opioid ago nist, has been validated for the quantification of fL opioid receptors in vivo (Frost et aI., 1985 (Frost et aI., , 1989 . [llC] Carfen tanil has been used in conjunction with [l 1 C]diprenor phine, a nonselective opioid antagonist, for the estima tion of non-fL receptor sites (Frost et aI., 1990) . Measure ments of combined 8 and K densities have been performed through the use of the nonsubtype-selective antagonist e 8 F]cyclofoxy (Carson et aI., 1993) .
Although much progress has been made on the in vitro localization of 8-opioid sites in the mammalian brain (Mansour et aI., 1993) , a suitable tracer for selective in vivo imaging in humans has not been previously avail able. This is of interest for the investigation of the role of 8-opioid receptors in normal and pathologic brain func tion in human subjects. As examples, preclinical data suggest that 8-opioid receptors are involved in seizure kindling and threshold (Tortella et aI., 1983) , and in the reinforcing effects of psycho stimulants (Jones and Holtz man, 1992; Menkens et aI., 1992) .
Naltrindole, a selective, high-affinity 8-opioid recep-tor antagonist, is a non peptide compound that is centrally active after peripheral administration in the rat (Porto ghese et a!., 1990). This compound is 700-fold and 3000fold more selective for ;) than for /Jand for K sites, respectively. Yamamura et a!. (1992) have characterized eH]naltrindole binding in rat brain homogenates, dem onstrating its high affinity for;) sites (Kd = 37 pmol/L). eH]Naltrindole shows high binding densities in neocor tical regions and basal ganglia, and moderate to low in hippocampus and thalamus (Drower et a!., 1993) after the known distribution of ;)-opioid receptors. Recently, a positron-emitting analog of naltrindole has been synthe sized in our laboratories by methylation of the indole nitrogen with [ Il C]iodomethane (Lever et a!., 1992 (Lever et a!., , 1994 . This methylated analog, NI' -([ ll C]methyl) nal trindole (e I C]MeNTI), retains the ;)-opioid receptor af finity and specificity of naltrindole. Lever et a1. (1992) have shown that [ II C]MeNTI administered intravenously permeates the blood-brain barrier, has a distribution in mouse brain that correlates with ;) binding in vitro, and that its binding in vivo is selectively blocked by ;) but not /Jor K antagonists. The distribution of [ 1l C]MeNTI in human brain has been demonstrated by PET (Madar et a!., 1996) . [ II C] MeNTI also has been used to show in creased ;)-opioid receptors in patients with temporal lobe epilepsy (Madar et a!., 1997) .
Here we examine a variety of methodologic alterna tives for the quantification of [ 11 C]MeNTI binding to ;)-opioid receptors in the human brain with PET. Both kinetic and nonkinetic approaches were applied to the data that were obtained through dynamic PET studies, after the bolus administration of high specific activity C I C]MeNTI to healthy human subjects.
METHODS

Subjects and PET acquisition
Eight young healthy subjects (mean age 31 ± 7 years), seven men and one woman, were recruited by advertisement and gave written informed consent to study participation. The subjects were screened by history and physical and neurologic exami nations. They had no history of medical, neurologic, or psy chiatric disorders; current use of psychoactive medications; or drug abuse.
An intravenous line was placed in an antecubital vein and an arterial catheter in the radial artery at the level of the wrist. Scanning was performed with aGE 4096 ± PET scanner (Gen eral Electric, Milwaukee, WI, U.S.A.), which acquires IS si multaneous slices with a separation between planes of 6.S mm. Before data acquisition, each volunteer was fitted with a ther moplastic face mask that was used in conjunction with x-ray computed tomography to localize the planes for the PET study and to eliminate subject motion. The planes selected for imag ing were standardized as follows: the glabellar-inion line was visually located on the computed tomography scan. An imaging plane that intersected the amygdalae, parallel to the glabellar inion line, was selected as the fourth PET plane. The masks were worn during the PET study, allowing alignment of the PET scanner slices to the glabellar-inion line and the standard ization of imaging planes across subjects.
After subject positioning in the scanner gantry, a lO-minute transmission scan (6RGe/6 8 Ga source) was performed for at tenuation correction immediately before the PET study. The [1 1 ClMeNTI was synthesized as previously described (Lever et aI., 1992) , and approximately 20 mCi were administered intra venously as a bolus (mean specific activity 2000 Ci/mmol, range 1107 to 4030 at the time of administration). Twenty-five dynamic PET scans (6 x 30 seconds, S x 1 minute, S x 2 minutes, 9 x 8 minutes) were acquired over 90 minutes. Four of the subjects were scanned twice, before and after the oral ad ministration of 100 mg naltrexone, approximately 1 hour before scanning. The images were smoothed to a final in-plane resolution of 7.7 mm at full-width half-maximum. An image then was gen erated for placement of 4 x 4 pixel (8 x 8 mm) regions of interest by averaging serial images obtained from scans cover ing the entire scanning period to provide gross anatomical land marks. Regions of interest were placed bilaterally on the pari etal, cingulate, occipital, and frontal cortices, cerebellum, thala mus, caudate, and putamen. The average activity (nCilcm3) in these regions then was quantified for each of the scanning intervals, producing activity data as a function of time.
Analysis of blood and plasma radioactivity
After radiotracer administration, approximately 20 arterial blood samples were collected in rapid succession for the first 3 minutes. An additional 20 samples were obtained during the remaining 87 minutes of the scan. The blood samples were centrifuged for S minutes at 2000 rpm. The plasma portion was withdrawn and counted for 1 minute in a gamma counter.
The proportion of metabolized [I I ClMeNTI in plasma was determined from arterial blood samples obtained before injec tion and at S, 10, IS, 30, 4S, 60, 7S, and 90 minutes after injection. The first four samples were 8 mL, and the remaining, 16 mL. These samples were centrifuged at 2000 rpm for S minutes, the plasma removed and passed through an activated C I 8 reverse-phase Sep-Pak (Waters Associates, Milford, MA, U.S.A.). The eluent was washed with 0.1 mmollL ammonium formate and eluted with 100% methanol. The methanol fraction was diluted with an aqueous solution of 2% triethylamine and 3% acetic acid to a final solution of 40% methanol. This solu tion was passed through a C I 8 reverse-phase analytical HPLC column (Waters Associates). The HPLC mobile phase was composed of 1: 1 acetonitrile and methanol (40%) and HPLC grade water buffered with 2% triethylamine and 3% acetic acid (60%). The HPLC flow rate was set at 3 mL/min. Extraction efficiencies for the parent compound and radiolabeled metabo lites were calculated and corrected for at each step of the Sep Pak separation. The preinjection blood sample, with e 1 C]MeNTI added, was used as a control to determine whether metabolites were produced in vitro and the extraction effi ciency of the parent drug. A sample of blood obtained 90 minutes after tracer administration, with high metabolite con tent, was used to calculate the metabolite extraction fraction. The total concentration of radioactivity in plasma then was corrected for the presence of radiolabeled metabolites by mul tiplying the plasma concentration by the fraction of unchanged drug using linear interpolation. Further details on these proce dures can be found in prior publications (Frost et aI., 1989; Price et aI., 1993; Sadzot et aI., 1991) . Briefly, the HPLC system was equipped with two opposed 12.7-cm (S-inch) NaI (Tl) detectors, a strip chart recorder, and a computer interface. Each radioactive peak was automatically integrated and the decay corrected back to the time of sample injection into the column. The percentage of total activity corresponding to un metabolized [IIC]MeNTI then was calculated for each time point.
The free fraction of [I 1 ClMeNTI in plasma (fl) was deter mined as previously described for [IICldiprenorphine and [IIC]flumazenol (Sadzot et aI., 1991; Price et aI., 1993) . Before tracer administration, a blood sample was obtained from each of four subjects. Fresh tracer, in equal amounts, was added to l-mL aliquots of plasma and 50 mmollL Tris buffer (pH 7.4 at room temperature). Centrifree micropartition systems (Amicon, Bedford, MA, U.S.A.) were loaded with equal portions (� 0.4 mL) of these standard samples then centrifuged for 20 minutes at 1500 rpm in a fixed-angle (3SO) rotor centrifuge. The value of fl was calculated using the following relation:
where X is the ratio of plasma ultrafiltrate to plasma standard, Y is the ratio of buffer ultrafiltrate to buffer standard (�l), and w is the water content of plasma, 0.94 ml water/ml plasma (Altman, 1961) .
Theory and kinetic methods
In this work, six different approaches were used to analyze e I ClMeNTI kinetic data. These analyses involved the curve fitting of two-and three-compartment models to the data, graphical analyses, determination of the apparent volume of distribution during a late scan, and a single-scan estimate of specific binding obtained from a late scan.
General three-compartment model. The regional two-and three-compartment methods of analyses were based on a more complex four'compartment system, previously described in work from our laboratory (Frost et aI., 1989) and other authors (Frey et aI., 1985; Koeppe et aI., 1991) . Practically, the use of this model is precluded in most cases by its complexity and the increased variance associated with the calculation of six sepa rate rate constants when only a single dose of tracer is admin istered. Therefore, in this work, a three-compartment model was investigated. This model consists of one vascular and two tissue compartments, differing from the four-compartment model in that the free and nonspecific ally bound tracer com partments are combined into a single compartment. Such a configuration assumes rates of exchange between free and non specifically bound tracer that are rapid relative to tracer trans port across the blood-brain barrier and tracer-receptor associa tion and dissociation. Following the scheme of Koeppe et al. (1991) , the set of differential equations that describe the ex change between compartments are defined as follows:
where C F+NS ' Cs, and C represent the concentrations of com bined free and nonspecifically bound, specifically bound, and total tracer concentrations, respectively; CB V represents the blood volume (BV) contribution of radioactivity in the brain region. The kinetic parameters governing the transfer of tracer between compartments then are defined as follows: where F is CBF (mL min-I mL -I ), E is the single-pass extrac tion fraction of the ligand across the blood-brain barrier, fl is the free fraction of ligand in plasma, PS is the capillary per meab!lity surface area product (mL min-I mL-I), DV F+NS is the dlstnbutlOn volume of free and nonspecific ally bound li gand, as estimated from the cerebellum in each individual study; kon is the bimolecular association rate between ligand and receptor (nmol L -I min-I), Bmax is the density of available receptors for binding (nmol L -I ), and koff is the dissociation rate of ligand from receptor (min-I). The free fraction of drug in brain, f2, may be determined from the following relation (Mintun et aI., 1984) :
The ratio of K/k2' (or distribution volume of free and non specifically bound tracer, DY F+NS) was determined after the administration of naltrexone, a competitive antagonist, by mod eling kinetic data from a region of negligible o-opioid receptor concentration, the cerebellum. Calculation of f2 allows the de termination of k3 = konBmax from the data. This approach to the estimation of DV F+NS is based on two primary assumptions. First, there is a negligible concentration of receptors in cerebel lum after blockade with naltrexone. Second, DV F+NS is ap proximately the same across brain regions, and the tracer dis tribution in the cerebellum adequately reflects this volume.
Three-compartment, jour-parameter estimation (model A). Since negligible dissociation of tracer from receptor was ob served during the time period of the PET scan (see Results), the value of k4 was constrained to 0 to reduce variability in the parameter estimation that otherwise would result. Therefore, a three-compartment, four-parameter (K I , k2', k3', BY) kinetic model was applied to the [IIClMeNTI time-activity data.
Three-compartment, three-parameter estimation (model B). To reduce the variability in the estimation of k3' for curve fits to specific-binding data, the distribution volume of free and nonspecifically bound tracer (DV F+NS) was specifically con strained. For each subject, the cerebellar DV F+NS was deter mined using a two-compartment model (three parameters-K I , k2', and BY-were estimated), and this value was used as a constraint during curve fits to the specific binding data. Since the value of k4 was experimentally found to be = 0, only K1, k3', and BY were simultaneously determined for the remainder of the regions.
Two-compartment, three-parameter estimation (model C). A two-compartment, three-parameter kinetic model consisting of a vascular compartment and a single tissue compartment was applied to the specific binding data as a further means of model simplification. Three rate constants (K I , k2", and BV) are cal culated for this system. The definition of KI remains the same as in models A and B, and kz" is defined as follows:
k2"=KI/(DYF+DVN S +DVs)=KI/DVT (min-I)
where DV T (or K/kz") is the total distribution volume of the tracer in the combined tissue compartments. As described by Koeppe et al. (1994) , the appropriateness of this model relies on rapid rates of association and dissociation relative to tracer transport across the blood-brain barrier. Second, the value of KINETIC ANALYSIS OF lI C-MENTI 959 DV s is large relative to DV F+NS such that DV T is reflective of receptor concentration rather than nonspecific binding. Optimal fits to the PET data for models A, B, and C were obtained using standard nonlinear least -squares curve fitting with Marquardt's method of minimization (Bevington, 1969) . Time delay and BY parameters were included in the models. The time delay factor reflects the difference in time for the tracer to reach the radial artery and brain tissue. Similarly to Koeppe et al. (199 1) , this factor was determined for each study by fitting the first 10 minutes of plasma and PET data for whole brain slices at four different scanning planes (3, 5, 8, and 10) with a two-compartment model in which BV was assumed to be 3.5%. The average of the time delays for the four slices then was used to constrain this parameter in further model fits for each subject. The BY parameter, which accounted for contri butions to brain activity measured by PET from the metabo lized and unmetabolized drug in blood, was allowed to iterate with each of the model fits described here.
Graphical analysis: Patlak slope. The graphical analysis de scribed by Gjedde (1982) and Patlak et al. (1983) has been used to measure the net accumulation of tracer in an irreversible compartment. The procedure entails graphing the activity in the region of interest divided by plasma activity (region of interest! plasma) versus normalized time « SC p (t) dt)/C p (T». After an initial uptake period, this plot affords a linear portion with a slope equal to
This equation assumes that after a certain period of time, nonspecific and free compartments have reached equilibrium (the slope becomes linear), and that there is negligible tracer dissociation from the specifically bound tracer compartment (k4 "" 0). In the specific case of ["ClMeNTI, the plotted data became linear after 13 minutes for all brain regions, and only data after that period were used in the estimations of the slope K. The slope then is proportional to both K, and k3'.
Normalized regional tracer concentration Normalization to metabolite-corrected plasma activity. Tissue measures were normalized to metabolite corrected plasma at late times after injection. After bolus administration, this ratio provides an es timate of the apparent volume of distribution (Y J (Carson et aI., 1993) .
Normalization to activity injected. The measure of regional tissue radioactivity concentration of activity at a late time after injection is the most simplified approach used here. The tissue concentrations are normalized to injected dose (mCi) to allow comparison between subjects. This method assumes that tracer equilibrium is rapid and that at late time points nearly all brain activity arises from specifically bound drug. Such an approach does not require blood sampling or mathematical analysis and is frequently used in the estimation of tracer activity in brain when blood sampling is not available or practical.
Computer simulations
Computer simulation studies were performed to investigate the errors associated with the parameter estimation by the vari ous quantitative methods. First, estimates of the rate constants for this radiotracer were obtained using the most complex com partment model that we were able to use for all subjects (three compartment estimation of K" k2', and k3' and BV, with k4 = o (Eq. 1 through 3). The rate constants for all subjects then were averaged, as were their metabolite-corrected arterial input functions. The rate constants K, and k3' then were modified to examine how variations in either transport rate or receptor binding may influence the data estimated with a given model and to test the validity of assuming irreversible or reversible binding. Noise-free PET data then were simulated using the general three-compartment model equations. Each method of analysis then was applied to the simulated data to assess the accuracy of each approach. In the case of the three compartment method, the rate constant k4 was allowed to iter ate.
Statistics
Comparisons between the model fits were obtained using a modification of the Akaike information criterion (AIC) (Akaike, 1974) , defined as AIC = -n In(SSQ) -2p, where n is the number of data points, SSQ is sum of squared errors, and p is number of parameters. Larger values denote better fits.
Results are expressed as the mean ± 1 SD. When specifically indicated in the text, data variability is expressed as the percent coefficient of variation [%COY = (SD .;-mean) x 100].
RESULTS
Blood and plasma radioactivity
The overall extraction efficiencies for the Sep-Pak C IS columns ranged from 70 ± 10% for the lO-minute plasma sample to 80 ± 4% for the 75-minute sample. No detect able metabolites were formed in vitro.
The HPLC chromatograms showed the parent com pound peak (retention time"" 7.5 minutes) throughout the study and two primary metabolite peaks (retention time "" 3.5 minutes and"" 4.5 minutes) as early as 5 minutes after injection. Poorer resolution of parent and metabolite peaks were noted in the 90-minute HPLC chromatogram; this was attributed to low levels of radioactivity in plasma and the larger extent of parent compound me tabolism . A representative plasma time-activity curve before and after metabolite correction is shown in Fig. 1 . The average proportions of unmetabolized tracer in plasma decreased from 86 ± 4% at 5 minutes to 34 ± 7% at 90 minutes after injection. The free fraction of tracer in plasma (fl) was calculated for four of the subjects and averaged 0.074 ± 0.013.
Regional tracer distribution and tracer kinetic analyses Figure 2 (first row) presents four representative PET slices obtained from one of the subjects , averaged from 34 to 70 minutes after injection. Higher tracer concen trations at these times are observed in neocortex and basal ganglia, areas known to be rich in 8-opioid recep tors . Lack of significant tracer activity in the cerebellum also is observed at these times. In the second row of Fig .  2 , PET images from the same subject were processed similarly, approximately 1 hour after the oral adminis tration of 100 mg of naltrexone . Significant displacement of tracer is observable in regions known to contain 8-opi oid receptors (i.e ., neocortex, basal ganglia, thalamus), with negligible changes in tracer activity in the cerebel lum.
Typical time-activity curves of [ 11 C]MeNTI in re gions with high (putamen), intermediate (frontal cortex), and low receptor densities (thalamus, cerebellum) are presented in Fig . 3 . A lower degree of binding and faster clearance is observed in the thalamus, as well as a greater retention of tracer in the putamen relative to frontal cor tex. Average peak whole-brain tracer activity for the eight subjec t s was 0.56 ± 0.13 f.LCi/mL brain for doses ranging from 16 to 28 mCi . A low peak brain uptake of tracer coupled with low radioactivity concentrations in plasma and difficulty in resolving the 90-minute metabo lite chromatogram resulted in poor data quality in the last two scan periods (74 to 90 minutes after injection), which were not used for the analyses presented . As described earlier, the application of the general three-compartment model (non-zero k4) to the data re vealed that the dissociation rate constant k4 was negli gible and had high intersubject parameter variability and
.. uncertainty in its estimation (data not shown). Therefore, k4 was subsequently fixed to 0 for the data presented. A summary of results for each of the applied analytical methods is presented in Table 1 . The variability of the specific binding parameter was largest for the most complex model (k3' for model A), which corresponds to a three-compartment configuration with four estimated parameters (K1, k2', k3', and BV). The variability in k3' was lower when model B was applied to the data (DV F+NS for specific binding curve fits was specifically constrained to cerebellar DV F+NS value). The DV F+NS calculated by model A averaged 8 ± 4 in areas of high receptor concentration (cortical regions and basal ganglia). Similarly, cerebellar DV F+NS values averaged 9 ± 2 for all subjects and were not significantly c· · �.
. 4 (£I different from those of brain regions with high specific binding (paired two-tailed t test, P > 0.05), supporting the feasibility of the simplification introduced in model B. With this simpler approach, in which only K 1 , k3', and BV were fitted to the data, intersubject variability was reduced, with %COV ranging from 12 to 40% . Similar performance was observed for the two-compartment model (calculation of DVT) and the graphical method (Patlak) , although the uncertainty of the latter method was considerable in areas with low receptor concentra tions (cerebellum and thalamus). The nonkinetic ap proaches, apparent volume of distribution at 70 minutes after injection (Va) , and tracer concentration in a late scan (70 minutes after injection) normalized to injected dose and yielded variability estimates in the range of 16% to 39%. The rank order of the specific receptor binding param eters estimated with each of these approaches were highly correlated with receptor concentrations obtained from equilibrium studies in vitro by other authors (Pfeiffer et aI., 1982) (Table 1) . On the other hand, for the nonkinetic analysis, Va and ratio of late scan activity to injected dose, the range of values obtained was se verely restricted, compared with in vitro or kinetic analy sis results. This restricted range of values for the various binding-related measures appeared to result from both an overestimation in areas of low receptor concentration and an underestimation in areas of high receptor content (confirmed in simulation studies; data not shown). Since both of the nonkinetic methods of analysis assume tracer equilibrium during the scanning period, a nonequilibrium condition even at late times after injection is the likely reason for these results.
The AIC values improved with the three-compartment configuration in all regions: from 81 in the two compartment configuration in thalamus, to 83 using a three-compartment model with DV F + NS fixed to cerebel lar values. Similarly, in frontal cortex it improved from 99 to 108, and in putamen, from 83 to 91. No improve-ments in the fits were observed when DV F + NS was not fixed from cerebellar values with exception of the thala mus. In this area, a small improvement was noted from the constrained (AIC = 83) to the unconstrained model (AIC = 85). Three-compartment model fits (k4 = 0) are shown in Fig. 3 . Rate constants (K 1 through k3) obtained with the three compartment model are presented in Table  2 . Two compartment fits consistently underestimated the observed values during the later time points, confirming that the assumption of significant tracer-receptor disso ciation during the study period is not valid for this ra diotracer.
Computer simulations
The accuracy of various quantification models to de scribe and differentiate changes in tracer transport and receptor binding were tested in simulation experiments. In these, the rate of tracer transport (K1) and the receptor binding parameter (k3') were varied over a wide range of values, and noiseless data were simulated based on the predetermined rate constants using a three-compartment model equation. Values represent the mean and % coefficients of variation (in pa renthesis) of rate constants obtained from eight healthy volunteers, using a three-compartment model. Parameter estimation was based on values of K/k2' fixed from cerebellar fits in which k3 and k4 were assumed to be negligible, therefore ret1ecting DV NS+F (mean ± SD, 9 ± 2). The parameter konBmax' ( = k3) was calculated from k3' obtained from a constrained three-compartment, three-parameter (Klo k3'o and BV) model, assuming a free fraction of tracer in plasma of 0.074. whereas changes in k3 were not linearly replicated by the receptor measu re of th is model. In Figs. 4A through C, the performance of the quan tification me � hods, which appeared to be adequate based on the results of Table 1 , is presented. We simulated a range of K, changes from -100 to +200% of the original data (obtained from the frontal cortex of a representative subject). The putative receptor measure obtained from the graphical analysis (Fig. 4A ) was demonstrated to be highly sensitive to modifications in the transport rate of k31/k2 poorer the two-compartment fits, with systematic under estimations of the observed values by the end of the observation period (90 minutes). Longer observation pe riods may have compensated for the increases in k3 val ues, but those are impractical in actual experiments be cause of the short half-life of carbon-II. In Figs. 4D through 4F , the sensitivity of the various methods to simulated changes in k3' was explored. In the case of the graphical analysis (Fig. 4D) , the sensitivity of the Patlak slope to detect changes in receptor density was limited at high k3' values. The relation between slope and simulated receptor binding became progressively nonlinear when increases in more than 50% of the origi nal values in frontal cortex were simulated. Considerably more linear relations were observed for the two-and three-compartment configurations (Figs. 4E and 4F) . However, because the data were originally obtained from a three-compartment model, it is possible that the results may have been biased toward better fits for this model.
A related issue is the condition of flow limitation de scribed in detail by other authors in the study of tracers with slow ligand-receptor dissociation rates (Frey et aI., 1992; Koeppe et aI., 1994) . Exploration of a possible flow-limitation condition also was performed using com puter-simulated data. The calculated tissue response at a late time after injection (70 minutes) was plotted against the simulated ratio k3'/k2' (Koeppe et aI., 1994) . As shown in Fig. 5 , at ratios of k3' 1k2' above '" l.5, the activity present in the late scan becomes progressively nonlinear with the simulated increase in k3'. The k3' 1k2' ratios observed experimentally in brain regions of healthy volunteers (Table 2 ) ranged from 0.3 to 1.1, be low the nonlinear region of the graph. This should theo retically allow a good definition of binding densities in areas of high receptor concentration when tracer kinetic analyses are applied. Nonlinearity, with the resulting constriction of values, would be observed only when the actual receptor concentrations in the tissue of interest are higher than 50% above those observed in the basal gan glia (the highest binding region for this tracer), corre sponding to k3' values higher than 0.045, approximately. Figure 2 shows data obtained from a representative healthy subject before and after administration of 100 mg of naltrexone orally. Examination of the time-activity curves showed constant blockade over the scanning pe riod with this long-acting opioid antagonist. K J and K/ k2' values were similar between blocked and unblocked studies for all regions examined, including the cerebel lum (two-tailed, paired t tests, P > 0.05). For the four subjects in which two scans were performed, at baseline and after naltrexone administration, mean percent reduc tions in regional k3' values after displacement were 68 ± 12% in frontal cortex, 72 ± 20% in occipital cortex, 62 ± 11 % in parietal cortex, 70 ± 12% in putamen, 57 ± 15% in caudate nucleus, and 41 ± 21 % in thalamus. The dif-ferences in mean percent blockade between regions probably result from uncertainties in the estimation of k3'. These data include one subject who, because of dif ficulties in radiotracer synthesis, was scanned approxi mately 3 hours after administration of 100 mg of nal trexone, in which the degree of [ ll C]MeNTI displace ment was much lower than in other experiments. Without inclusion of that data set, k3' values were reduced in the range of 40% to 95% across brain regions after naltrex one administration.
DISCUSSION
In this work, [ I I C]MeNTI and PET were used to ob tain in vivo specific binding measures in healthy human subjects by applying a variety of analytic methods. The different methodologic approaches also were tested us ing computer simulation studies. These studies demon strated that kinetic analyses (e.g., compartmental model ing or graphical analyses) yielded less biased binding related measures compared with the nonkinetic methods. Specifically, this work demonstrated that a constrained three-compartment model was the analytic method of choice.
The nonkinetic binding measures that were evaluated corresponded to ratios of late scan data to either metabo lite-corrected plasma or to the injected dose (mCi). These methods showed regional rank order of values that were highly correlated with previously reported in vitro bind ing data from human brain (Pfeiffer et aI., 1982) and the autoradiographic distribution of o-opioid receptors and 0 receptor mRNA in experimental animals (Drower et aI., 1993; Mansour et aI., 1993) . Tracer uptake was highest in basal ganglia and neocortical regions and low in thala mus and cerebellum. However, a significant degree of nonspecific binding is noted in the later region, which, at least based on the animal literature, should have negli gible binding levels. Without further analysis, these mea sures appear to be adequate for the estimation of radio tracer-specific binding with the advantage of allowing short scanning periods (radiotracer binding estimated from a single scan performed late after radiotracer ad ministration) and simpler methods of analysis.
These two nonkinetic quantification models rely on the assumption that tissue-plasma equilibrium has been achieved for all brain regions. In the absence of equilib rium, specific binding can be overestimated in regions with low receptor concentration (e.g., thalamus) and un derestimated in regions with high receptor concentration (e.g., basal ganglia) because of regional differences in the time to reach equilibrium, which depends on the re ceptor concentration and radioligand dissociation rates of the region. The biases introduced by these methods are pronounced for radiotracers that have small dissociation rates relative to the rate of its clearance from plasma (Carson et aI., 1993; Frost et aI., 1989; Koeppe et aI., 1994) , and therefore can be considered irreversible. In addition, the range of the specific binding parameter val ues (for regions of high to low receptor density) is con stricted for the single scan analyses and leads to diffi culty in distinguishing regional specific binding differ ences.
An additional difficulty in attempting to quantify re ceptor densities from nonkinetic data is the possibility that the activity present in brain regions may be depen dent on the degree of tracer transport from plasma to tissue. When the lack of equilibration during the scan ning period is combined with high degrees of receptor binding relative to the rate of tracer transport from plasma to tissue, the observed concentration of tracer in the tissue will be limited in areas of high receptor den sity. This flow-limited condition has been observed for tracers that, similarly to [ II C]MeNTI, present small rates of transport from tissue back to plasma (Frey et aI., 1992; Koeppe et aI., 1994) . When k3' (Bmaxkon), is large rela tive to k2 in a specific region of interest, all available tracer in tissue is bound, and accumulation of the tracer in that region becomes proportional to the amount of tracer delivered (flow limited) (Koeppe et aI., 1994) . This may contribute to the biases observed with the non kinetic methods of analysis (underestimation in areas of high receptor density) and may deteriorate the accuracy of kinetic approaches in the same regions by providing the model with flow limited data. In the case of [ 11 C]MeNTI, simulation studies were performed in which the rate constant k3' obtained from a representa tive subject was progressively increased with respect to k2'. This tracer demonstrated favorable ratios of k3' Ik2' across brain regions in scanned data (range of 0.3 to 1. 1), whereas flow limitation effects were clearly observed only at k3' ik2' ratios higher than 1.5 in the simulation studies. Under these circumstances, PET data obtained over 70 minutes after tracer administration appear to be adequate to obtain measures that are unbiased by flow limitation effects, provided that the methods used are otherwise valid in their assumptions.
For the kinetic methods (least-squares curve fitting and graphical analysis techniques), the parameter bias and variability depended on the complexity of the model configuration. The computer simulation studies defined when the specific binding parameters were independent of changes in radiotracer delivery, and described the sen sitivity of the parameter to differences in receptor den sity. The variability in the receptor estimates was most pronounced with the more complex model tested, a three-compartment configuration in which K1, k3', k2', and BV contributions were fitted to the data. Coefficients of variation when individual rate constants were calcu lated ranged from 20% to 79% across brain regions, making it impractical for its routine use in the estimation J Cereb Blood Flow Metab, Vol. 19, No. 9, 1999 of receptor densities in human subjects. A variation of this model assumed that an approximation to the com bined nonspecific and free volumes of distribution could be obtained from a region with negligible 8-opioid re ceptor binding (i.e., cerebellum) (Mansour et aI., 1987; Pfeiffer et aI., 1982) . This simplification also assumes that, in addition to equilibration between nonspecific and free compartments and plasma tracer concentration, the volume of distribution in those compartments is constant across brain regions and similar to that in the nonspecific binding region. This assumption is supported by the lack of significant differences between the DV F+NS values obtained in regions with low and high specific binding, and also by the lack of improvement in model fits across brain regions, when the DV F+NS parameters are allowed to vary in the estimation procedure, although fits for areas with low receptor concentration (e.g., thalamus) were minimally improved when the parameters were al lowed to freely vary. Similar approaches have been ap plied successfully in other radiotracer PET binding stud ies (Frost et aI., 1989; Koeppe et aI., 1991; Price et aI., 1993; Sadzot et aI., 1991; Sawada et aI., 199 1) .
The ability of the various models to accurately identify changes in apparent binding values from changes in tracer delivery is of importance in the application of the data analysis to patient data. Changes in regional CBF, which impact on the amount of tracer delivered to the tissue, are frequently found in various diseases (e.g., Alz heimer's disease, seizure disorders) (Bonte et aI., 1993; Engel, 1988; Frackowiak et aI., 1981) or physiologic states (i.e., during pharmacologic or cognitive chal lenges) (Holthoff et aI., 1991; Zohar et aI., 1989 , Zubieta et aI., 1998 . If the specific binding process cannot be separated from radiotracer delivery effects, then differ ences in regional tracer uptake could be misinterpreted as differences in regional receptor concentration.
The kinetic methods that specifically describe radio tracer transport and specific binding (conventional two and three-compartment models) were less sensitive to simulated changes in the plasma-to-tissue transport rate than those that did not (e.g., graphical analysis). How ever, the assumption of significant dissociation of the tracer from the specific binding compartment by the two compartment model is not valid in this case. The fact that this tracer appears to have irreversible binding charac teristics during the study period limits the number of approaches that can be used for its quantification. The graphical approach is easy to implement and uses a simple linear regression for the calculation of its binding parameter (Patlak et aI., 1983) . This method produced acceptable precision in its estimates, especially in areas of high receptor concentrations (%COV values from 19% to 34% in areas of high receptor density, 43% to 47% in low specific binding regions). Uncertainties in the estimation of the slope in low specific binding re-gions may result both from a high proportion of nonspe cific binding and high K I values for this radiotracer. The computer simulations of the [ II C]MeNTI data demon strated that the Patlak specific binding parameter (slope = K 1 k3' 1k2' + k3') was highly sensitive to alterations in KI. Similar results have been reported for other radio tracers (Koeppe et a!., 1994) . Without the separate de termination of KI from the initial uptake phase of the plot, this model does not appear to be adequate for the unbiased calculation of receptor densities with [ 11 C]MeNTI. Another graphical alternative, in which the blood plasma term of the Patlak plot is substituted by tissue measurements in an area devoid of specific bind ing, may be less sen sitive to transport changes (Patlak and Blasberg, 1985) . Although this method initially was tested for the analysis of scanned [ II CJMeNTI data, it showed large degrees of intersubject variability in the binding estimates and was abando ned as a routine method of analysis.
The linearity of the receptor density measure with re spect to simulated changes in k3' also was tested for the various quantification models using computer simula tions . Binding densities estimated fro m the slope of Pat lak plots became nonlinear when increases larger than 50% in k3' were simulated for the frontal cortex . This corresponded to values of k3' larger than 0.051 . As pre viously shown for other tracers with negligible dissocia tion from receptor sites (Koeppe et a!., 1994) , as k3' increases, the term k3' /[k2' + k3'] approaches unity. In this situation, the equation that defines the slope, Kl k3'/ [k2' + k3'], becomes proportional to KI (flow depen dent), with K I then being a limiting factor for the accu rate estimation of binding densities. In the case of two and three-compartment models, these effects were less prominent and apparent only at large increases in the simulated k3'.
Since none of the available 8-opioid selective antago nists are currently approved for hu man administration at saturating doses, displacement of [ I I C]MeNTI binding by a competing ligand was tested after the administration of the nonselective antagonist naltrexone. This drug has lower affinity for 8 receptors than for fL or K sites, and the tracer displacement was high but not complete for most of the brain regions studied . Regarding the selec tivity of [ 11 C]MeNTI for 8-opioid sites , this has been demonstrated after in vivo administration in experimental animals (Lever et aI ., 1992) . Moreover, the rank order of binding densities identified with [ 11 C]MeNTI in the hu man brain is highly correlated with the known distribu tion of 8 receptors and is clearly different from that re ported for other tracers labeling fL (Frost et a!., 1989) , fL and K (Carson et a!., 1993; Kawai et aI ., 1990; Sawada et aI., 1991) , or all opioid sites (Frost et a!., 1990; Sadzot et aI., 1991) .
In summary, a simplified three -compartment model, in which nonspecific and free tracer volumes of distribution were estimated from a brain region devoid of specific binding, proved to describe accurately the data obtained with PET and [ 11 C]MeNTI. This method presents the advantages of acceptable precision in the estimation of binding parameters, excellent correlation with equilib rium in vitro data described by other authors, a linear relation between the model binding estimates and simu lated binding densities, and independence from changes in tracer transport across the blood-brain barrier . These properties permit the application of the methodology pre sented here to the study of 8-opioid receptor involvement in both physiologic and pathologic brain function. 
